Systemic lupus erythematosus, endothelial progenitor cells and intracellular Ca2+ signaling: A novel approach for an old disease

Komici, Klara; Faris, Pawan; Negri, Sharon; Rosti, Vittorio; Garcı́a-Carrasco, Mario; Mendoza‐Pinto, Claudia; Berra‐Romani, Roberto; Cervera, Ricard; Guerra, Germano; Moccia, Francesco

doi:10.1016/j.jaut.2020.102486

Cited by 12 publications

(8 citation statements)

References 250 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third, ECFCs’ angiogenic behavior is typically compromised in the presence of cardiovascular risk factors that predispose to the onset of ischemic disorders; this further contributes to discouraging the use of circulating ECFCs for autologous cell therapy [ 15 , 59 , 110 , 115 ]. For instance, the frequency and/or vasoreparative potential of circulating ECFCs are remarkably reduced with CAD [ 120 ], aging [ 121 ], diabetes [ 122 ], abdominal aortic aneurysm [ 123 ], venous thromboembolic disease [ 124 ], congenital diaphragmatic hernia [ 125 ], systemic lupus erythematosus [ 126 ], and the pediatric Moyamoya disease (MMD) [ 127 ]. In addition, ECFCs’ angiogenic behaviour is impaired in patients affected by human immunodeficiency virus (HIV), which has long been associated with cardiovascular disorders [ 128 ].…”

Section: Manipulation Of Pro-angiogenic Signaling Pathways To Imprmentioning

confidence: 99%

Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy

Faris

Negri

Perna

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Cardiovascular disease (CVD) comprises a range of major clinical cardiac and circulatory diseases, which produce immense health and economic burdens worldwide. Currently, vascular regenerative surgery represents the most employed therapeutic option to treat ischemic disorders, even though not all the patients are amenable to surgical revascularization. Therefore, more efficient therapeutic approaches are urgently required to promote neovascularization. Therapeutic angiogenesis represents an emerging strategy that aims at reconstructing the damaged vascular network by stimulating local angiogenesis and/or promoting de novo blood vessel formation according to a process known as vasculogenesis. In turn, circulating endothelial colony-forming cells (ECFCs) represent truly endothelial precursors, which display high clonogenic potential and have the documented ability to originate de novo blood vessels in vivo. Therefore, ECFCs are regarded as the most promising cellular candidate to promote therapeutic angiogenesis in patients suffering from CVD. The current briefly summarizes the available information about the origin and characterization of ECFCs and then widely illustrates the preclinical studies that assessed their regenerative efficacy in a variety of ischemic disorders, including acute myocardial infarction, peripheral artery disease, ischemic brain disease, and retinopathy. Then, we describe the most common pharmacological, genetic, and epigenetic strategies employed to enhance the vasoreparative potential of autologous ECFCs by manipulating crucial pro-angiogenic signaling pathways, e.g., extracellular-signal regulated kinase/Akt, phosphoinositide 3-kinase, and Ca2+ signaling. We conclude by discussing the possibility of targeting circulating ECFCs to rescue their dysfunctional phenotype and promote neovascularization in the presence of CVD.

show abstract

Section: Manipulation Of Pro-angiogenic Signaling Pathways To Imprmentioning

confidence: 99%

Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy

Faris

Negri

Perna

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Firstly, the frequency of circulating ECFCs is rather low, ranging from 0.28 to 15 ECFCs/10 7 mononuclear cells, which is insufficient to achieve a therapeutically relevant outcome (Moccia et al, 2017(Moccia et al, , 2018a. Secondly, ECFCs' angiogenic activity is severely compromised by CVD (Sung et al, 2013;Mauge et al, 2014;Su et al, 2017;Komici et al, 2020) and by cardiovascular risk factors (Shelley et al, 2012;Jarajapu et al, 2014;Mena et al, 2018), which may ultimately lead to ischemia-related disorders. Thirdly, ECFCs' angiogenic activity could be further reduced once they reach the harsh microenvironment of ischemic tissues.…”

Section: Current Limitations Of Ecfcs For Therapeutic Angiogenesismentioning

confidence: 99%

Towards Novel Geneless Approaches for Therapeutic Angiogenesis

2021

Self Cite

View full text Add to dashboard Cite

Cardiovascular diseases are the leading cause of mortality worldwide. Such a widespread diffusion makes the conditions affecting the heart and blood vessels a primary medical and economic burden. It, therefore, becomes mandatory to identify effective treatments that can alleviate this global problem. Among the different solutions brought to the attention of the medical-scientific community, therapeutic angiogenesis is one of the most promising. However, this approach, which aims to treat cardiovascular diseases by generating new blood vessels in ischemic tissues, has so far led to inadequate results due to several issues. In this perspective, we will discuss cutting-edge approaches and future perspectives to alleviate the potentially lethal impact of cardiovascular diseases. We will focus on the consolidated role of resident endothelial progenitor cells, particularly endothelial colony forming cells, as suitable candidates for cell-based therapy demonstrating the importance of targeting intracellular Ca2+ signaling to boost their regenerative outcome. Moreover, we will elucidate the advantages of physical stimuli over traditional approaches. In particular, we will critically discuss recent results obtained by using optical stimulation, as a novel strategy to drive endothelial colony forming cells fate and its potential in the treatment of cardiovascular diseases.

show abstract

“…Third, ECFCs' angiogenic behavior is typically compromised in the presence of cardiovascular risk factors which predispose to the onset of ischemic disorders; this further contributes to discourage the use of circulating ECFCs for autologous cell therapy [15,119,120,126]. For instance, the frequency and/or vasoreparative potential of circulating ECFCs are remarkably reduced with CAD [131] aging [132], diabetes [133], abdominal aortic aneurysm [134], venous thromboembolic disease [135], congenital diaphragmatic hernia [136], systemic lupus erythematosus [137], and the pediatric Moyamoya disease [138]. In addition, ECFCs' angiogenic behaviour is also impaired in patients affected by human immunodeficiency virus (HIV), which has long been associated with cardiovascular disorders [139].…”

Section: Manipulation Of Pro-angiogenic Signaling Pathways To Improvementioning

confidence: 99%

Therapeutic Potential of Endothelial Colony Forming Cells in Ischemic Disease: Strategies to Improve Their Regenerative Efficacy

Faris

Negri

Perna

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Cardiovascular disease (CVD) comprises a group of heart and circulatory disorders, which are regarded as a global medical issue with high prevalence and mortality rates. Currently, vascular regenerative surgery represents the most employed therapeutic option to treat ischemic disorders, even though not all the patients are amenable to surgical revascularization. Therefore, more efficient therapeutic approaches are urgently required to promote neovascularization. Therapeutic angiogenesis represents an emerging strategy that aims at reconstructing the damaged vascular network by stimulating local angiogenesis and/or promoting de novo blood vessel formation according to a process known as vasculogenesis. Circulating endothelial colony forming cells (ECFCs), in turn, represent truly endothelial precursors able to aggregate into bidimensional tube networks and to originate patent vessels. Accordingly, ECFCs provide the most rationale and promising cellular candidate for therapeutic purposes. The current review provides a brief outline on the origin and characterization of ECFCs and a summary of the progress in preclinical studies aiming at assessing their efficacy in a variety of ischemic disorders, including AMI, PAD, ischemic brain disease and retinopathy. We also describe how to enhance the vasoreparative potential of ECFCs by boosting specific pro-angiogenic signalling pathways either pharmacologically or through gene manipulation. Taken together, these observations suggest that ECFCs represent a useful strategy to treat ischemic diseases.

show abstract

Systemic lupus erythematosus, endothelial progenitor cells and intracellular Ca2+ signaling: A novel approach for an old disease

Cited by 12 publications

References 250 publications

Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy

Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy

Towards Novel Geneless Approaches for Therapeutic Angiogenesis

Therapeutic Potential of Endothelial Colony Forming Cells in Ischemic Disease: Strategies to Improve Their Regenerative Efficacy

Contact Info

Product

Resources

About